5. Park JS, Choi YS, Yoo CK. Emergency use authorization of in-vitro diagnostics for infectious disease. Public Health Weekly Report. 2017; 10:555–9.
6. CLSI. Quantitative molecular methods for infectious disease. Approved guideline. 2nd ed. CLSI MM06-A2. Wayne, PA: Clinical and Laboratory Standards Institute;2010.
7. Kim MN, Ko YJ, Seong MW, Kim JS, Shin BM, Sung H. Analytical and clinical validation of six commercial Middle East Respiratory Syndrome coronavirus RNA detection kits based on real-time reverse-transcription PCR. Ann Lab Med. 2016; 36:450–6.
Article
8. Kim YJ, Sung H, Ki CS, Hur M. COVID-19 testing in South Korea: current status and the need for faster diagnostics. Ann Lab Med. 2020; 40:349–3509.
Article
9. Sung H, Yong D, Ki CS, Kim JS, Seong MW, Lee H, et al. Comparative evaluation of three homogenization methods for isolating Middle East Respiratory Syndrome coronavirus nucleic acids from sputum samples for real-time reverse transcription PCR. Ann Lab Med. 2016; 36:457–62.
Article
10. Lee MK, Kim S, Kim MN, Kweon OJ, Lim YK, Ki CS, et al. Survey of clinical laboratory practices for 2015 Middle East Respiratory Syndrome coronavirus outbreak in the Republic of Korea. Ann Lab Med. 2016; 36:154–61.
Article